CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content

Zydelig for Chronic Lymphocytic Leukemia – Details

Project Number PC0057-000
Brand Name Zydelig
Generic Name Idelalisib
Strength 100mg and 150mg tablets
Tumour Type Leukemia
Indication Chronic Lymphocytic Leukemia
Funding Request In combination with rituximab for the treatment of patients with relapsed chronic lymphocytic leukemia (CLL)
Review Status Complete
Pre Noc Submission No
NOC Date March 27, 2015
Manufacturer Gilead Sciences, Inc.
Sponsor Gilead Sciences, Inc.
Submission Date April 7, 2015
Submission Deemed Complete April 14, 2015
Submission Type Initial
Prioritization Requested Not Requested
Stakeholder Input Deadline ‡ April 21, 2015
Check-point meeting May 28, 2015
pERC Meeting July 16, 2015
Initial Recommendation Issued July 30, 2015
Feedback Deadline ‡ August 14, 2015
Final Recommendation Issued August 18, 2015
Notification to Implement Issued September 2, 2015
Therapeutic Area Chronic lymphocytic leukemia
Recommendation Type Reimburse with clinical criteria and/or conditions

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.